Bayer Aktiengesellschaft (BAYRY)
| Market Cap | 55.44B +78.2% |
| Revenue (ttm) | 51.84B -1.7% |
| Net Income | -1.99B |
| EPS | -2.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.48 |
| Dividend | 0.02 (0.17%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 226,982 |
| Open | 14.14 |
| Previous Close | 13.84 |
| Day's Range | 14.08 - 14.25 |
| 52-Week Range | 7.48 - 15.23 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 15.90 (+12.61%) |
| Earnings Date | Aug 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BAYRY stock is "Buy." The 12-month stock price target is $15.9, which is an increase of 12.61% from the latest price.
News
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Bayer
Pharma's 2026 recovery puts Bayer, Eli Lilly and Johnson & Johnson in focus as innovation and M&A offset pricing and patent headwinds.
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.
Voyageur moves to end North America’s reliance on imported contrast media
Calgary-based company owns the Frances Creek barite resource in British Columbia, which supplies the barium. It is developing an iodine extraction project in Oklahoma alongside Bayer. It is designing ...
Missouri Court Grants Delay for Bayer’s Roundup Settlement Hearing
Bayer's $7.25 billion Roundup deal gets new September court date
A Missouri judge on Thursday agreed to delay a hearing to consider Bayer's $7.25 billion proposed settlement of cases alleging that its weedkiller Roundup causes cancer, rescheduling an approval heari...
Bayer price target raised to EUR 61 from EUR 50 at JPMorgan
JPMorgan raised the firm’s price target on Bayer (BAYRY) to EUR 61 from EUR 50 and keeps an Overweight rating on the shares.
Bayer seeks short delay to $7.25 billion Roundup settlement hearing
Bayer has asked a Missouri court to reschedule a hearing to evaluate the company's $7.25 billion proposed settlement of cases alleging that its popular weedkiller Roundup causes cancer.
Bayer Stock Jumps 3.7% as Seed Profit Tops Forecasts
Bayer Stock Jumps 3.7% as Seed Profit Tops Forecasts
Bayer Aktiengesellschaft Earnings Call Transcript: Q2 2026
Sales grew 3% to EUR 24.3 billion in H1 2026, with strong performance in Crop Science and new pharma products offsetting declines in mature brands. Litigation risks eased after a favorable U.S. Supreme Court ruling, and capital structure was strengthened by Apollo's equity investment and new bond issuance.
Bayer Aktiengesellschaft Quarterly report: Q2 2026
Bayer Aktiengesellschaft has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bayer Aktiengesellschaft Slides: Q2 2026
Bayer Aktiengesellschaft has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Bayer Aktiengesellschaft Earnings release: Q2 2026
Bayer Aktiengesellschaft released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bayer Aktiengesellschaft Slides: Corporate presentation
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
Bayer raises FY26 sales view to EUR 44.7B-EUR 46.7B from EUR 44.5B-EUR 46.5B
The company said, “Bayer (BAYRY) has affirmed its currency-adjusted Group guidance for full-year 2026 for all metrics except net financial debt, which it now expects to come in lower than…
Bayer says ‘advancing’ on strategic priorities
Bayer (BAYRY) is also advancing its other strategic priorities, CEO Bill Anderson said, pointing to progress in rejuvenating the Pharmaceuticals pipeline and executing the Five-Year Framework to impro...
Bayer Aktiengesellschaft Q2 Earnings Call Highlights
Bayer Aktiengesellschaft ETR: BAYN said first-half sales rose 3% on a currency- and portfolio-adjusted basis to €24.3 billion, as growth in Crop Science and Consumer Health offset pressure in parts of...
Bayer Aktiengesellschaft Earnings Call Transcript: Q2 2026
Sales grew 3% to EUR 24.3 billion in H1 2026, with margin gains in Crop Science and resilience in Pharma. Litigation risk eased after a favorable Supreme Court ruling, and capital structure was strengthened by a EUR 3 billion Apollo investment and $5 billion bond issue.
Bayer Aktiengesellschaft Quarterly report: Q2 2026
Bayer Aktiengesellschaft has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bayer Aktiengesellschaft Earnings release: Q2 2026
Bayer Aktiengesellschaft released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bayer Returns To Q2 Profit, Sales Edge Up; Confirms Outlook
LEVERKUSEN (dpa-AFX) - German pharmaceutical and biotechnology company Bayer AG (BYR.L) returned to profit in the second quarter, primarily helped by significantly lower other operating expenses.N...
Bayer Swings to Net Profit on Smaller Litigation Charges
The company said its 2026 sales and earnings forecasts were unchanged when adjusted for currency changes, and that year-end net debt would be lower than originally projected.
Agentic Marketers: Bayer, Zoom, and More Reveal Their Biggest AI Wins
Learn how the top marketers from Bayer, Zoom, and a health tech firm have implemented AI over the past month, and what they hope to accomplish over the next quarter.
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
Bayer: New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
New research by Economist Enterprise, supported by Bayer, highlights the potential of self-care to become a more integrated component of modern health systems The research underscores that self-ca...
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched...